Product news

Share this article:
GlaxoSmithKline announced the approval of Requip XL(ropinirole extended-release tablets) in the US for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The product should be available in pharmacies in mid-July 2008.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions